Dextrose And Sodium Chloride (dextrose and sodium chloride) - Dosing, PA Forms & Info (2026)
logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Dextrose And Sodium Chloride - Dextrose And Sodium Chloride injection, Solution

    Get your patient on Dextrose And Sodium Chloride - Dextrose And Sodium Chloride injection, Solution (Dextrose And Sodium Chloride)

    Medication interactionsSee all drug-to-drug interactions for this medication.
    card icon
    Prescribing informationPubMed™ news

    Dextrose And Sodium Chloride - Dextrose And Sodium Chloride injection, Solution prescribing information

    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    Prescribing Information
    Indications & Usage

    INDICATIONS AND USAGE

    These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes, calories and water for hydration.

    Dosage & Administration

    DOSAGE AND ADMINISTRATION

    These solutions are for intravenous use only.

    Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

    When a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. Carefully avoid infiltration.

    In the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of fluid containing 0.9% sodium chloride (154 mEq each of sodium and chloride).

    Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.

    Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    Pediatric Use

    There is no specific pediatric dose. The dose is dependent on weight, clinical condition, and laboratory results. See WARNINGS and PRECAUTIONS .

    Contraindications

    CONTRAINDICATIONS

    These solutions are contraindicated where the administration of sodium or chloride could be clinically detrimental.

    Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.

    Adverse Reactions

    ADVERSE REACTIONS

    Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

    Too rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended. (See DOSAGE AND ADMINISTRATION .)

    Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential.

    Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect.

    The physician should also be alert to the possibility of adverse reactions to drug additives diluted and administered from the plastic container. Prescribing information for drug additives to be administered in this manner should be consulted.

    If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

    Description

    DESCRIPTION

    (See chart below for quantitative information.)

    Dextrose and Sodium Chloride Injections USP are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents. These products are intended for intravenous administration.

    The formulas of the active ingredients are:

    Ingredients Molecular Formula Molecular Weight
    Sodium Chloride USP NaCl 58.44
    Hydrous Dextrose USPReferenced Image 198.17

    Composition – Each 100 mL contains: Concentration of Electrolytes
    (mEq/liter)
    Hydrous Dextrose USP Sodium Chloride USP Calories per liter Calculated Osmolarity
    mOsmol/liter
    pH
    Solution Sodium Chloride
    Water for Injection USP qs
    3.3% Dextrose and 0.30% Sodium Chloride Injection USP 3.3 g 0.3   g 51 51 110 270 4.5 (3.5–6.5)
    5% Dextrose and 0.9% Sodium Chloride Injection USP 5   g 0.9   g 154 154 170 560 4.4 (3.5–6.5)
    5% Dextrose and 0.45% Sodium Chloride Injection USP 5   g 0.45 g 77 77 170 405 4.4 (3.5–6.5)
    5% Dextrose and 0.33% Sodium Chloride Injection USP 5   g 0.33 g 56 56 170 365 4.4 (3.5–6.5)
    5% Dextrose and 0.20% Sodium Chloride Injection USP 5   g 0.2   g 34 34 170 320 4.4 (3.5–6.5)
    10% Dextrose and 0.45% Sodium Chloride Injection USP 10   g 0.45 g 77 77 340 660 4.3 (3.5–6.5)
    10% Dextrose and 0.20% Sodium Chloride Injection USP 10   g 0.2   g 34 34 340 575 4.3 (3.5–6.5)

    Not made with natural rubber latex, PVC or DEHP.

    The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

    Addition of medication should be accomplished using complete aseptic technique.

    The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. Refer to the Directions for Use of the container.

    Pharmacology

    CLINICAL PHARMACOLOGY

    Dextrose and Sodium Chloride Injections USP provide electrolytes and calories and are a source of water for hydration. All are capable of inducing diuresis depending on the clinical condition of the patient.

    Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

    Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.

    Dextrose provides a source of calories. Dextrose is readily metabolized, may decrease losses of body protein and nitrogen, promotes glycogen deposition and decreases or prevents ketosis if sufficient doses are provided.

    How Supplied/Storage & Handling

    HOW SUPPLIED

    Dextrose and Sodium Chloride Injections USP are supplied sterile and nonpyrogenic in EXCEL ® Containers. The 1000 mL containers are packaged 12 per case; the 500 mL and 250 mL containers are packaged 24 per case.

    Canada DIN NDC REF Size
    3.3% Dextrose and 0.30% Sodium Chloride Injection USP
    01927981 0264-7608-00 L6080-00 1000 mL
    0264-7608-10 L6081-00 500 mL
    5% Dextrose and 0.9% Sodium Chloride Injection USP
    01924435 0264-7610-00 L6100 1000 mL
    0264-7610-10 L6101 500 mL
    5% Dextrose and 0.45% Sodium Chloride Injection USP
    01927531 0264-7612-00 L6120 1000 mL
    0264-7612-10 L6121 500 mL
    0264-7612-20 L6122 250 mL
    5% Dextrose and 0.33% Sodium Chloride Injection USP
    0264-7614-00 L6140 1000 mL
    0264-7614-10 L6141 500 mL
    5% Dextrose and 0.20% Sodium Chloride Injection USP
    01927558 0264-7616-00 L6160 1000 mL
    0264-7616-10 L6161 500 mL
    0264-7616-20 L6162 250 mL
    10% Dextrose and 0.45% Sodium Chloride Injection USP
    0264-7622-00 L6220 1000 mL
    10% Dextrose and 0.20% Sodium Chloride Injection USP
    0264-7623-20 L6232 250 mL

    Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.

    Data SourceWe receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
    Report Adverse Event
    Interactions Banner
    Check medication interactionsReview interactions as part of your prescribing workflow

    Dextrose And Sodium Chloride - Dextrose And Sodium Chloride injection, Solution PubMed™ news

      Show the latest PubMed™ articles for Dextrose And Sodium Chloride - Dextrose And Sodium Chloride injection, Solution